Browse > Article
http://dx.doi.org/10.4014/jmb.1703.03039

Enterobacter aerogenes ZDY01 Attenuates Choline-Induced Trimethylamine N-Oxide Levels by Remodeling Gut Microbiota in Mice  

Qiu, Liang (State Key Laboratory of Food Science and Technology, Nanchang University)
Yang, Dong (State Key Laboratory of Food Science and Technology, Nanchang University)
Tao, Xueying (State Key Laboratory of Food Science and Technology, Nanchang University)
Yu, Jun (Jiangxi University of Traditional Chinese Medicine)
Xiong, Hua (State Key Laboratory of Food Science and Technology, Nanchang University)
Wei, Hua (State Key Laboratory of Food Science and Technology, Nanchang University)
Publication Information
Journal of Microbiology and Biotechnology / v.27, no.8, 2017 , pp. 1491-1499 More about this Journal
Abstract
Trimethylamine N-oxide (TMAO), which is transformed from trimethylamine (TMA) through hepatic flavin-containing monooxygenases, can promote atherosclerosis. TMA is produced from dietary carnitine, phosphatidylcholine, and choline via the gut microbes. Previous works have shown that some small molecules, such as allicin, resveratrol, and 3,3-dimethyl-1-butanol, are used to reduce circulating TMAO levels. However, the use of bacteria as an effective therapy to reduce TMAO levels has not been reported. In the present study, 82 isolates were screened from healthy Chinese fecal samples on a basal salt medium supplemented with TMA as the sole carbon source. The isolates belonged to the family Enterobacteriaceae, particularly to genera Klebsiella, Escherichia, Cronobacter, and Enterobacter. Serum TMAO and cecal TMA levels were significantly decreased in choline-fed mice treated with Enterobacter aerogenes ZDY01 compared with those in choline-fed mice treated with phosphate-buffered saline. The proportions of Bacteroidales family S24-7 were significantly increased, whereas the proportions of Helicobacteraceae and Prevotellaceae were significantly decreased through the administration of E. aerogenes ZDY01. Results indicated that the use of probiotics to act directly on the TMA in the gut might be an alternative approach to reduce serum TMAO levels and to prevent the development of atherosclerosis and "fish odor syndrome" through the effect of TMA on the gut microbiota.
Keywords
Trimethylamine N-oxide; trimethylamine; Enterobacter aerogenes; gut microbiota;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mejean V, Iobbi-Nivol C, Lepelletier M, Giordano G, Chippaux M, Pascal MC. 1994. TMAO anaerobic respiration in Escherichia coli: involvement of the tor operon. Mol. Microbiol. 11: 1169-1179.   DOI
2 Ocque AJ, Stubbs JR, Nolin TD. 2015. Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. J. Pharm. Biomed. Anal. 109: 128-135.   DOI
3 Romano KA, Vivas EI, Amador-Noguez D, Rey FE. 2015. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio 6: e02481.
4 Magoc T, Salzberg SL. 2011. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27: 2957-2963.   DOI
5 Bokulich NA, Subramanian S, Faith JJ, Gevers D, Gordon JI, Knight R, et al. 2013. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. Nat. Methods 10: 57-59.   DOI
6 Edgar RC. 2013. UPARSE: highly accurate OTUs equences from microbial amplicon reads. Nat. Methods 10: 996-998.   DOI
7 Wang Q, Garrity GM, Tiedje JM, Cole JR. 2007. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73: 5261-5267.   DOI
8 Suchodolski JS, Foster ML, Sohail MU, Leutenegger C, Queen EV, Steiner JM, Marks SL. 2015. The fecal microbiome in cats with diarrhea. PLoS One 10: e0127378.   DOI
9 Randrianarisoa E, Lehn-Stefan A, Wang X, Hoene M, Peter A, Heinzmann SS, et al. 2016. Relationship of serum trimethylamine N-oxide (TMAO) levels with early atherosclerosis in humans. Sci. Rep. 6: 26745.   DOI
10 Kim SG, Bae HS, Oh HM, Lee ST. 2003. Isolation and characterization of novel halotolerant and/or halophilic denitrifying bacteria with versatile metabolic pathways for the degradation of trimethylamine. FEMS Microbiol. Lett. 225: 263-269.   DOI
11 Mewies M, Packman LC, Mathews FS, Scrutton NS. 1996. Flavinylation in wild-type trimethylamine dehydrogenase and differentially charged mutant enzymes: a study of the protein environment around the N1 of the flavin isoalloxazine. Biochem. J. 317: 267-272.   DOI
12 Liffourrena AS, Lucchesi GI. 2014. Identification, cloning and biochemical characterization of Pseudomonas putida A (ATCC 12633) monooxygenase enzyme necessary for the metabolism of tetradecyltrimethylammonium bromide. Appl. Biochem. Biotechnol. 173: 552-561.   DOI
13 Kasprzak AA, Papas EJ, Steenkamp DJ. 1983. Identity of the subunits and the stoichiometry of prosthetic groups in trimethylamine dehydrogenase and dimethylamine dehydrogenase. Biochem. J. 211: 535-541.   DOI
14 Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, et al. 2014. ${\gamma}$-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 20: 799-812.   DOI
15 Denby KJ, Rolfe MD, Crick E, Sanguinetti G, Poole RK, Green J. 2015. Adaptation of anaerobic cultures of Escherichia coli K-12 in response to environmental trimethylamine-Noxide. Environ. Microbiol. 17: 2477-2491.   DOI
16 Hoyles L, Jimenez-Pranteda ML, Chilloux J, Myridakis A, Gauguier D, Nicholson JK, et al. 2015. Reduction of trimethylamine N-oxide to trimethylamine by the human gut microbiota: supporting evidence for 'metabolic retroversion'. Poster in Conference on Exploring Human Host-Microbiome Interactions in Health and Disease. Imperial College of London.
17 Zhu Y, Jameson E, Crosatti M, Schafer H, Rajakumar K, Bugg TD, Chen Y. 2014. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. USA 111: 4268-4273.   DOI
18 Chen Y, Patel NA, Crombie A, Scrivens JH, Murrell JC. 2011. Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase. Proc. Natl. Acad. Sci. USA 108: 17791-17796.   DOI
19 Ussher JR, Lopaschuk GD, Arduini A. 2013. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 231: 456-461.   DOI
20 Moller B, Hippe H, Gottschalk G. 1986. Degradation of various amine compounds by mesophilic clostridia. Arch. Microbiol. 145: 85-90.   DOI
21 Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. 2013. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19: 576-585.   DOI
22 Sekirov I, Russell SL, Antunes LC, Finlay BB. 2010. Gut microbiota in health and disease. Physiol. Rev. 90: 859-904.   DOI
23 Lee WJ, Hase K. 2014. Gut microbiota-generated metabolites in animal health and disease. Nat. Chem. Biol. 10: 416-424.   DOI
24 Tremaroli V, Backhed F. 2012. Functional interactions between the gut microbiota and host metabolism. Nature 489: 242-249.   DOI
25 Bennett BJ, Vallim TQDA, Wang Z, Shih DM, Meng Y, Gregory J, et al. 2013. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 17: 49-60.   DOI
26 Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. 2011. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 57-65.   DOI
27 Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. 2013. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368: 1575-1584.   DOI
28 Ulman CA, Trevino JJ, Miller M, Gandhi RK. 2014. Fish odor syndrome: a case report of trimethylaminuria. Dermatol. Online J. 20: 21260.
29 Kuka J, Liepinsh E, Makrecka-Kuka M, Liepins J, Cirule H, Gustina D, et al. 2014. Suppression of intestinal microbiotadependent production of pro-atherogenic trimethylamine Noxide by shifting L-carnitine microbial degradation. Life Sci. 117: 84-92.   DOI
30 Brugere JF, Borrel G, Gaci N, Tottey W, O'Toole PW, Malpuech-Brugere C. 2014. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes 5: 5-10.   DOI
31 Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, et al. 2015. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat. Commun. 6: 6498.   DOI
32 Wu W-K, Panyod S, Ho C-T, Kuo C-H, Wu M-S, Sheen L-Y. 2015. Dietary allicin reduces transformation of L-carnitine to TMAO through impact on gut microbiota. J. Funct. Foods 15: 408-417.   DOI
33 Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. 2015. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163: 1585-1595.   DOI
34 Chen ML, Yi L, Zhang Y, Zhou X, Ran L, Yang J, et al. 2016. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. mBio 7: e02210-e02215.
35 Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, et al. 2015. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 56: 22-37.   DOI
36 Gregory JC, Buffa JA, Org E, Wang Z, Levison BS, Zhu W, et al. 2015. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 290: 5647-5660.   DOI